Allergy最新文献

{"title":"Biomarkers Are Consistent With Patient‐Reported Allergic Sensitization in Topical Steroid Withdrawal","authors":"Aditi Vijendra, Nadia Shobnam, Jalin Jordan, Pranav Thota, Ian A. Myles","doi":"10.1111/all.70068","DOIUrl":"https://doi.org/10.1111/all.70068","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"10 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145133564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of House Dust Mite Immunotherapy in Chinese Allergic Rhinitis Patients With Diverse Sensitization Patterns: A Multicenter Study (COVER Study).","authors":"Qingxiu Xu,Xuan Yuan,Wang Liao,Hao Chen,Qing Jiang,Lin Yang,Jin Liu,Le Li,Nan Huang,Wenjing Li,Yaqi Yang,Dongxia Ma,Jun Bai,Zhihai Xie,Rongfei Zhu","doi":"10.1111/all.70072","DOIUrl":"https://doi.org/10.1111/all.70072","url":null,"abstract":"BACKGROUNDAllergen immunotherapy (AIT) is the only etiological treatment for allergic rhinitis (AR) patients, yet the impact of allergen sensitization patterns on AIT efficacy remains unclear. This study aimed to assess the effectiveness of subcutaneous immunotherapy (SCIT) using a native house dust mite (HDM) allergen extract in Chinese AR patients with diverse HDM sensitization patterns.METHODSThis prospective multicenter study across three allergy centers in China enrolled patients aged 5-65 diagnosed with HDM-induced AR. Serum-specific IgE testing for nine HDM components (Der p1, Der p2, Der p23, Der f1, Der f2, Der p5, Der p7, Der p10, Der p21) categorized patients into two groups: Group A with sensitization limited to major allergen components and Group B with sensitization to minor components with or without major components. Both groups underwent 1 year of HDM SCIT (Allergopharma, Germany), whose efficacy was assessed using the visual analogue scale (VAS) and combined symptom medication scores (CSMS). Serum IgE and IgG4 levels against the nine HDM components were measured pre- and post-treatment, and SCIT-related adverse reactions were recorded.RESULTSThe study enrolled 168 patients, with 75 in Group A and 93 in Group B. Group B patients had higher asthma prevalence and elevated baseline HDM sIgE and total IgE levels. After 1 year, Group B showed significantly greater CSMS reduction (67.70% vs. 59.09%, p = 0.03) and VAS improvement (66.67% vs. 50.00%, p = 0.01) compared to Group A. Group A had increased new sensitization risk to minor allergens (Der p5, Der p7, Der p21). No significant difference in SCIT efficacy was observed between patients with and without new sensitization. Both groups exhibited increased sIgG4 levels against all nine HDM allergens, with a more pronounced elevation of sIgG4 levels to Der p21 observed in Group B compared to Group A (p = 0.02). SCIT-related adverse reactions were comparable (p > 0.05).CONCLUSIONSThe native HDM allergen extract demonstrates efficacy in Chinese AR patients with varying sensitization patterns. It offers enhanced benefits for patients sensitized to minor allergens with or without major allergens of HDM, positioning it as the preferred option for individuals with AR.TRIAL REGISTRATIONChinese Clinical Trial Registry identifier: ChiCTR2300078642.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"319 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145134262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive Analysis of Type 2 Innate Lymphoid Cell (ILC2) Heterogeneity and Identification of CD81 as a Marker for Pathogenic IL-13+ ILC2s in Atopic Dermatitis Skin.","authors":"Mai Nishimura,Yasutomo Imai,Yoshiaki Matsushima,Keiichi Yamanaka","doi":"10.1111/all.70077","DOIUrl":"https://doi.org/10.1111/all.70077","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"16 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145134263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mandatory Preemptive Skin Testing and Its Impact on Penicillin Allergy Labeling Across Different Healthcare Settings in Mainland China and Hong Kong.","authors":"Weihong Shi,Lanting Wang,Shengan Chen,Philip Hei Li,Xiaoqun Luo","doi":"10.1111/all.70065","DOIUrl":"https://doi.org/10.1111/all.70065","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"18 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145127036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline Serum Tryptase: Sex- and Age-Specific Reference Intervals in the Pediatric and Adult Population.","authors":"Yannick Chantran,Hélène Novakowski,Amandine Vial-Dupuy,Christine Bouz,Pol André Apoil,Simone Choi,Eric Fromentin,Julien Goret,Patricia Mathieu,Moïse Michel,Ariane Nemni,Edouard Sève,Céline Roda,Fanny Rancière,Joana Vitte,Isabelle Momas,Caroline Klingebiel, ","doi":"10.1111/all.70069","DOIUrl":"https://doi.org/10.1111/all.70069","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"24 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145127038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anaphylaxis Induced by Goat's and Sheep's Milk-A Rare Entity in Europe.","authors":"Ewa Cichocka-Jarosz,Sabine Dölle-Bierke,Nikolaos G Papadopoulos,Margitta Worm","doi":"10.1111/all.70051","DOIUrl":"https://doi.org/10.1111/all.70051","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"40 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145127081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut Microbiota-Derived Secondary Bile Acids Regulate Allergic Diseases.","authors":"Lan Yang,Zhen Lin,Gaofeng Wang","doi":"10.1111/all.70076","DOIUrl":"https://doi.org/10.1111/all.70076","url":null,"abstract":"","PeriodicalId":122,"journal":{"name":"Allergy","volume":"88 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145127076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future Directions.","authors":"Marjolein S de Bruin-Weller,Celeste M Boesjes,Roselie A Achten,Lisa A Beck,Alan D Irvine,Christian Vestergaard,Marlies de Graaf,Femke van Wijk,Daphne S Bakker,Stephan Weidinger","doi":"10.1111/all.70061","DOIUrl":"https://doi.org/10.1111/all.70061","url":null,"abstract":"Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases worldwide. The clinical presentation of AD is heterogeneous and is characterized by a relapsing and remitting course. Most patients suffer from mild AD while approximately 5% to 20% experience severe disease activity, which often requires systemic treatment. Before 2017, systemic treatment options were limited to broad immunosuppressants, which often had significant toxicity and limited effectiveness. Advances in understanding AD pathophysiology have led to the development of targeted biologic therapies, including dupilumab, tralokinumab, lebrikizumab, and nemolizumab. These monoclonal antibodies specifically block key pro-inflammatory cytokines involved in AD, improving disease control and symptom relief. Dupilumab, the first approved biologic, inhibits IL-4 and IL-13 signaling, while tralokinumab and lebrikizumab selectively block IL-13. Nemolizumab targets IL-31, which plays a crucial role in pruritus. This review summarizes primarily real-world data on the effectiveness and safety of these biologics, providing clinical guidance for their use and management of side effects. It also briefly discusses promising therapeutic targets currently in phase 3 trials.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"19 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145127129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correspondence: Accuracy Is Not Enough: Stability‐Aware Feature Selection for Reproducible Biomarker Discovery","authors":"Yoshiyasu Takefuji","doi":"10.1111/all.70075","DOIUrl":"https://doi.org/10.1111/all.70075","url":null,"abstract":"Random forest (RF) models can achieve high predictive accuracy, yet their model‐specific feature importances may be unstable and misleading. Using an allergy benchmark dataset (10,000 instances, 11 features), we compared five selection strategies—RF, logistic regression, feature agglomeration (FA), highly variable gene selection (HVGS), and Spearman correlation—evaluating cross‐validated accuracy with the top five features and after removing the top two (reselecting the top three). RF attained 0.9999 accuracy with the top five but fell to 0.8836 and showed unstable rankings; logistic regression maintained 0.9116 but was also unstable. FA, HVGS, and Spearman achieved near‐perfect accuracy (0.9999) with the top five and modest declines (0.9076–0.9116) with stable rankings. Results underscore that accuracy does not imply reliable importance; stability‐aware, model‐agnostic, or unsupervised methods better support reproducible biomarker discovery.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"29 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145116524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of the Arg16Gly β2-Adrenergic Receptor Polymorphism on Long-Term Mepolizumab Response and Clinical Remission in Severe Eosinophilic Asthma: A Genotype-Stratified, Multicenter Study.","authors":"Santi Nolasco,Evelina Fagone,Raffaele Campisi,Andrea Portacci,Giulia Scioscia,Corrado Pelaia,Angelantonio Maglio,Claudio Candia,Vitaliano Nicola Quaranta,Isabella Carrieri,Alessandro Saglia,Alessandro Vatrella,Girolamo Pelaia,Carlo Vancheri,Maria Pia Foschino Barbaro,Maria D'Amato,Giovanna Elisiana Carpagnano,Nunzio Crimi,Claudia Crimi, ","doi":"10.1111/all.70071","DOIUrl":"https://doi.org/10.1111/all.70071","url":null,"abstract":"BACKGROUNDβ2-adrenergic signaling promotes airway smooth muscle relaxation and limits the release of pro-inflammatory mediators by immune cells. The rs1042713 polymorphism encodes a glycine-to-arginine substitution (Arg16Gly) that enhances β2-receptor downregulation. We investigated the association of this polymorphism with the risk of severe eosinophilic asthma and its impact on the long-term effectiveness of mepolizumab and clinical remission.METHODSGenotypes from 102 patients with severe eosinophilic asthma receiving mepolizumab were compared with those from 31 individuals with mild asthma and 20 healthy controls. The severe-asthma cohort was followed for up to 24 months, and clinical data were collected at baseline and after 3, 6, 12, and 24 months of treatment. Analyses were stratified by Arg/Arg, Arg/Gly, and Gly/Gly genotypes.RESULTSEach additional Arg16 allele increased the odds of severe eosinophilic asthma by 2.61-fold (95% CI 1.48-4.59; p = 0.0001) relative to mild asthma and by 3.61-fold (95% CI 1.78-7.35; p < 0.0001) relative to healthy controls. Over 24 months of mepolizumab treatment, Arg/Arg patients had an increased risk of exacerbations (HR 2.3 [95% CI 1.03-5.20]; p = 0.0414) and poorer asthma control compared with Gly/Gly patients (ACT ≥ 20: 72.4% vs. 100%, p = 0.0308). Gly/Gly patients also experienced less decline in lung function. By month 24, each additional Gly16 allele increased the odds of achieving clinical remission by 2.86-fold (95% CI 1.20-6.81; p = 0.0170), defined as no annual exacerbations, no OCS, and ACT ≥ 20, and by 3.06-fold (95% CI 1.34-6.96; p = 0.0080) when including an FEV1 decline ≤ 5% from baseline.CONCLUSIONSThe Arg16 allele of the rs1042713 polymorphism increases the risk of severe eosinophilic asthma and may reduce the long-term efficacy of mepolizumab, whereas the Gly16 allele appears to confer better outcomes and higher remission rates.","PeriodicalId":122,"journal":{"name":"Allergy","volume":"82 1","pages":""},"PeriodicalIF":12.4,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145116752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}